Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 4.00p 3.75p 4.25p 4.00p 4.00p 4.00p 236,115 07:57:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 6.4 -3.6 -1.6 - 11.87

Deltex Medical (DEMG) Latest News

More Deltex Medical News
Deltex Medical Takeover Rumours

Deltex Medical (DEMG) Share Charts

1 Year Deltex Medical Chart

1 Year Deltex Medical Chart

1 Month Deltex Medical Chart

1 Month Deltex Medical Chart

Intraday Deltex Medical Chart

Intraday Deltex Medical Chart

Deltex Medical (DEMG) Discussions and Chat

Deltex Medical Forums and Chat

Date Time Title Posts
28/4/201714:26Deltex Medical - a British success story!8,722.00
13/3/201714:08Deltex Medical - winner or doomed to fail? 150.00
14/7/201411:16Deltex Medical-Optimal Growth Stock10,005.00
22/3/201209:04Deltex Medical - Past, Present and Future-
07/12/201111:57Deltex Medical - More key endorsements-

Add a New Thread

Deltex Medical (DEMG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Deltex Medical trades in real-time

Deltex Medical (DEMG) Top Chat Posts

Deltex Medical Daily Update: Deltex Medical Group is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 4p.
Deltex Medical Group has a 4 week average price of 3.63p and a 12 week average price of 3.63p.
The 1 year high share price is 5.75p while the 1 year low share price is currently 3.63p.
There are currently 296,741,733 shares in issue and the average daily traded volume is 48,757 shares. The market capitalisation of Deltex Medical Group is £11,869,669.32.
yump: Well the net result of the buying and selling at historic lows has been nothing for the last few days, so for every seller who has got bored, a buyer thinks its near the bottom. At the moment it seems to be a firmish bottom, rather than a wobbly one, so the interpretation could be mildly positive. At some point, if there is no more bad news for a share, the continual drops stop. Then it takes a while for the buying to outweigh the selling. Back in August/September there was more positive news on US, which appears to have caused a small spike, but the effect of that and the UK on the figures was unknown. Now things are a little more certain and the actual business problems caused by the UK falling, look likely to stabilise. Its possible the previous bad news and problems are all in the price at last and now its just a question of waiting for the results to show revenue starting to grow. I hope so as got quite a few around 4p now, on the basis that I think any tangible improvement will cause a rapid share price rise which will not come back down again. Fingers and other stuff crossed !
gbenson1: A rise in the share price would be nice, break even will come sooner rather than later, we need to be pushing PR and sales more in the US to get on the radar, someone is building a stake?
february 30th: It's not just the USA, it's the ROW. The relatively strong Euro must be helpful, while it lasts. As for the fall in the share price post update, I don't find it entirely convincing. The update was everything we expected, plus the 30 US accounts had been achieved, albeit quite a few months after Labor Day! Prior to the announcement there might have been some fear that the accounts were drying up, which has been allayed. If a couple more accounts could be announced by the end of February, that would suggest a minor-breakthrough.
zho: Equity Development: FY16 group revenues reached £6.3m in FY16 vs £6.2m (ex-research barter sales of £0.2m) marginally lower than the £6.4m total in FY15. KPI probe sales reached £5.4m (£5.2m) with sustained momentum from US revenues, up 40% to £1.9m in FY16, counterbalancing UK weakness. Looking ahead, with two new platform accounts added post year end, DEMG has reached a milestone of 30 US platform accounts, which could see higher margin US sales outperform other geographies for the first time in 2017. By contrast, as flagged, UK sales declined 26% vs FY15 to £1.9m as a result of attrition and the lack of advanced haemodynamic management within the NHS. Meanwhile, revenues from international sales grew 20% to £1.7m led by France, Scandinavia, Peru and Korea, illustrating the potential in these most ODM-receptive markets. The overall picture is of higher margin US sales on track to lead revenues from FY17. This, coupled with cost-cutting initiatives including in-house probe assembly leading to c £30,000 net savings/month, suggest margin expansion towards historical 70% levels is in sight. DEMG‘s end 2016 cash position of £0.6m, net of an £0.5m fund raise in July, provides short term funding. Pressure on sales has led to downgrades and a volatile 12-month share price performance. The current EV sales multiple of 2x implies expectations of further downgrades, although the current run rate in the US suggests DEMG could have reversed the overall financial downward trend. We will reinstate forecasts at the FY16 results due to be reported in the week of 20 March.
arf dysg: Any guesses as to why Lidco's share price and Deltex's share price have gone up today? I notice that Lidco, in its half-year report, says that it is the "clear market leader in the home market". Surely that wouldn't be a dig at anyone?
yump: I'm sure there's a lot of folk here who didn't realise that the share price had dropped from its peaks, so that's really helpful to know. Its just a shame that some super-clever folk couldn't have drawn in any lines down to 5p when the share price was 30p. Its probably worth posting on all the shares in the market with some lines showing what could happen on the downside. Then at least it will look like a prediction, rather than a statement of the bleeding obvious.
february 30th: If you look at the share prices of Deltex and Lidco from 2005 through to 2016, there is essentially no correlation: On the surface there does appear to be a small positive correlation, of 0.3. However when you strip out the impact of autocorrelation, the correlation disappears. So essentially they are unconnected. The correlation does change from year to year. The two years where you have had negative correlations, with one company's share price falling, and the other rising, are 2009 and 2016, to date: 2009 was when Lidco had its tie-up with Arrow, which arguably saved the company, even though the deal didn't give them a break-through in the US. This deal is used, e.g. by The Count, to demonstrate why partnerships would not necessarily be a good thing for Deltex. Looking at 2015 to 2016, we get the following: I suppose both Deltex and Lidco have been hit by reduced NHS spending, and the results of Lidco's disastrous Optimise trial have damaged both companies. I'm reminded of Boris the Dog's remark in "The Lady and the Tramp", in the dog pound: "Is like Gorky says in lower Dapts. Miserable being must find more miserable being. Then is happy". It seems likely that in the short-term both Deltex and Lidco will follow each other down, and I can't see good news from Lidco helping Deltex. Also, I think Deltex will continue falling without news, probably resting at 4p or lower by results. There is uneasiness about the cash situation, plus a worry that the US account targets may not be reached. Though hopefully there will be good news from the US soon, and the negative correlation in 2016 can be deepened.
djgrantb: This share price defies logic, almost 190k bought and 48k sold, share price down, the MMs are having a laugh.... Strong buys the other day, the share price rises before any trades go through and doesn't move a jot all day....
buywell2: The DEMG share price is not funny or laughing matter for many I would hazard
doglover2003: -- > Feb 30th DEMG management would certainly defend the company very determinedly and would not be recommending any offer to shareholders unless of several multiples of turnover and payable 100 per cent in cash. Therefore, I think you would find that DEMG management would make the Optimise Trial a very important issue for LIDCO shareholders. Any offer by LIDCO would probably produce a re-rating of DEMG and a hammering for LIDCO share price which would make the whole takeover unworkable. Even today LIDCO failed to produce evidence in support of their technology without mentioning DEMG in the same breadth as part of the trial. As for the DEMG share price, the substantial fall in the share price took place on very modest volumes. Conversely, it would not take mega volume to move the price in the opposite direction. DL
Deltex Medical share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170429 21:20:53